NATIONAL INSTITUTES OF HEALTH

🇺🇸United States

Country: 🇺🇸United States

Ownership: Subsidiary, Private

Established: 1948-01-01

Employees: 1K

Market Cap: -

Website: http://www.nidcr.nih.gov

Clinical Trials

Alanosine in Treating Patients With Progressive or Recurrent Malignant Gliomas

Phase 1

Completed

Conditions: Brain and Central Nervous System Tumors

First Posted Date: 2004-01-13

Last Posted Date: 2009-01-13

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 18

Registration Number: NCT00075894

Locations: 🇺🇸
H. Lee Moffitt Cancer Center and Research Institute at University of South Florida, Tampa, Florida, United States
🇺🇸
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States
🇺🇸
Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States

and more 2 locations

Gemcitabine, Carboplatin, and Bortezomib in Advanced or Recurrent Non-Small Cell Lung Cancer

Phase 2

Completed

Conditions: Recurrent Non-small Cell Lung Cancer
Stage IIIB Non-small Cell Lung Cancer
Stage IV Non-small Cell Lung Cancer

Interventions: Drug: gemcitabine hydrochloride
Drug: carboplatin
Drug: bortezomib

First Posted Date: 2004-01-13

Last Posted Date: 2013-02-28

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 99

Registration Number: NCT00075751

Locations: 🇺🇸
Southwest Oncology Group, San Antonio, Texas, United States

Imatinib Mesylate in Treating Patients With Recurrent or Persistent Uterine Cancer

Phase 2

Completed

Conditions: Recurrent Uterine Sarcoma
Uterine Carcinosarcoma

Interventions: Drug: imatinib mesylate
Other: laboratory biomarker analysis

First Posted Date: 2004-01-12

Last Posted Date: 2019-07-24

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 26

Registration Number: NCT00075400

Locations: 🇺🇸
Gynecologic Oncology Group, Philadelphia, Pennsylvania, United States

Triapine and Gemcitabine Hydrochloride in Gallbladder Cancer

Phase 2

Completed

Conditions: Stage IVA Gallbladder Cancer
Stage II Gallbladder Cancer
Stage IIIA Gallbladder Cancer
Stage IVB Gallbladder Cancer
Stage IIIB Gallbladder Cancer

Interventions: Drug: triapine
Drug: gemcitabine

First Posted Date: 2004-01-12

Last Posted Date: 2015-09-28

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 33

Registration Number: NCT00075504

Locations: 🇺🇸
Montefiore Medical Center, Bronx, New York, United States

Decitabine, Doxorubicin, and Cyclophosphamide in Treating Children With Relapsed or Refractory Solid Tumors or Neuroblastoma

Phase 1

Completed

Conditions: Recurrent Neuroblastoma
Unspecified Childhood Solid Tumor, Protocol Specific

Interventions: Drug: decitabine
Drug: doxorubicin hydrochloride
Drug: cyclophosphamide
Biological: filgrastim
Biological: pegfilgrastim
Other: laboratory biomarker analysis
Other: pharmacological study

First Posted Date: 2004-01-12

Last Posted Date: 2013-09-30

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 21

Registration Number: NCT00075634

Locations: 🇺🇸
Children's Oncology Group, Arcadia, California, United States

Neoadjuvant and Adjuvant Fenretinide Compared With Adjuvant Fenretinide Alone in Treating Patients Who Are Undergoing Surgical Resection For Recurrent Glioblastoma Multiforme

Phase 2

Terminated

Conditions: Adult Giant Cell Glioblastoma
Adult Glioblastoma
Adult Gliosarcoma
Recurrent Adult Brain Tumor

Interventions: Drug: fenretinide
Other: pharmacological study
Procedure: therapeutic conventional surgery
Other: laboratory biomarker analysis

First Posted Date: 2004-01-12

Last Posted Date: 2013-01-24

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 42

Registration Number: NCT00075491

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

CCI-779 in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer

Phase 2

Completed

Conditions: Adenocarcinoma of the Pancreas
Recurrent Pancreatic Cancer
Stage II Pancreatic Cancer
Stage III Pancreatic Cancer
Stage IV Pancreatic Cancer

Interventions: Drug: temsirolimus
Other: laboratory biomarker analysis

First Posted Date: 2004-01-12

Last Posted Date: 2013-01-17

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 40

Registration Number: NCT00075647

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Gefitinib in Treating Patients With Progressive Metastatic Neuroendocrine Tumors

Phase 2

Completed

Conditions: Gastrinoma
Glucagonoma
Insulinoma
Metastatic Gastrointestinal Carcinoid Tumor
Pancreatic Polypeptide Tumor
Recurrent Gastrointestinal Carcinoid Tumor
Recurrent Islet Cell Carcinoma
Somatostatinoma
WDHA Syndrome

Interventions: Drug: gefitinib
Other: laboratory biomarker analysis

First Posted Date: 2004-01-12

Last Posted Date: 2013-06-04

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 90

Registration Number: NCT00075439

Locations: 🇺🇸
Mayo Clinic, Rochester, Minnesota, United States

SU5416 in Treating Patients With Metastatic Kidney Cancer That Has Not Responded to Previous Treatment

Phase 2

Terminated

Conditions: Recurrent Renal Cell Cancer
Stage IV Renal Cell Cancer

Interventions: Drug: semaxanib

First Posted Date: 2004-01-01

Last Posted Date: 2013-01-23

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 50

Registration Number: NCT00009919

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Arsenic Trioxide in Treating Patients With Urothelial Cancer

Phase 2

Completed

Conditions: Recurrent Transitional Cell Cancer of the Renal Pelvis and Ureter
Recurrent Urethral Cancer
Transitional Cell Carcinoma of the Bladder
Ureter Cancer

Interventions: Drug: arsenic trioxide

First Posted Date: 2003-12-31

Last Posted Date: 2013-06-04

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 35

Registration Number: NCT00009867

Locations: 🇺🇸
Cancer and Leukemia Group B, Chicago, Illinois, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy